Working… Menu
Trial record 1 of 3 for:    VELCADE lupus
Previous Study | Return to List | Next Study

Velcade for Proliferative Lupus Nephritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01169857
Recruitment Status : Withdrawn (No participants were enrolled.)
First Posted : July 26, 2010
Last Update Posted : April 24, 2012
Weill Medical College of Cornell University
Information provided by (Responsible Party):
The Rogosin Institute

Brief Summary:
The primary objective is to test the safety and efficacy of Velcade to induce remission in WHO class III/IV/V lupus nephritis that are refractory to standard medications.

Condition or disease Intervention/treatment Phase
Lupus Nephritis Proteinuria Hematuria Drug: Velcade Phase 4

Detailed Description:
This exploratory single center, open-label, single treatment group assignment, safety, and efficacy study will enroll 14 patients with WHO class III/IV/V lupus nephritis. Subjects will receive 12 doses of Velcade to induce clinical remission.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Velcade for Proliferative Lupus Nephritis
Study Start Date : August 2010
Estimated Primary Completion Date : August 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Bortezomib

Arm Intervention/treatment
Experimental: Velcade Therapy Drug: Velcade
Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
Other Names:
  • Bortezomib
  • Proteasome inhibitor

Primary Outcome Measures :
  1. Proteinuria [ Time Frame: 1 year ]
    Quantification of 24 hr urinary protein.

Secondary Outcome Measures :
  1. Renal function [ Time Frame: 1 year ]
    Serum creatinine and GFR

  2. Lupus activity score [ Time Frame: 1 year ]
    Assessment of SELENA-SLEDAI

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. ACR criteria for lupus (minimum 4 out of 11).
  2. Biopsy proven WHO class III or IV or V lupus nephritis with clinical activity.
  3. GFR must be greater or equal to 30 cc/min/1.73 m2.
  4. Proteinuria must exceed 1000 mg per day except for WHO class V lupus nephritis, daily proteinuria must be greater or equal to 2000 mg.
  5. Primary therapy for active disease must have been given at least 6 months prior to protocol enrollment for WHO lupus III/IV.

Exclusion Criteria:

  1. Serum creatinine of more than 3.0 mg/dL on repeated testing.
  2. Greater than 50% fibrosis on renal biopsy.
  3. Platelet count of less than 30× 109/L.
  4. Absolute neutrophil count of less than 1.0 × 109/L.
  5. Greater than or equal to Grade 1 peripheral neuropathy.
  6. Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure.
  7. Hypersensitivity to Velcade, boron or mannitol.
  8. Serious medical conditions and infections (including HIV, HCV, HBV) or psychiatric illness.
  9. Known history of untreated positive PPD.
  10. Serious complications from systemic lupus such as cerebral lupus and severe active infections.
  11. Diagnosed or treated for another malignancy within 3 years of enrollment.
  12. Greater than 1.5x upper limit of normal total bilirubin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01169857

Layout table for location information
United States, New York
The Rogosin Institute
New York, New York, United States, 10021
Sponsors and Collaborators
The Rogosin Institute
Weill Medical College of Cornell University
Layout table for investigator information
Principal Investigator: Choli Hartono, MD The Rogosin Institute
Layout table for additonal information
Responsible Party: The Rogosin Institute Identifier: NCT01169857    
Other Study ID Numbers: X05321
1003010960 ( Other Identifier: Weill Cornell Medical College IRB )
First Posted: July 26, 2010    Key Record Dates
Last Update Posted: April 24, 2012
Last Verified: April 2012
Keywords provided by The Rogosin Institute:
Proliferative lupus nephritis
WHO class III/IV/V lupus nephritis
Proteasome inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Nephritis
Lupus Erythematosus, Systemic
Kidney Diseases
Urologic Diseases
Urination Disorders
Urological Manifestations
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Proteasome Inhibitors
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action